Biomarin's previously rejected hemophilia drug gets special status at the FDA
The FDA in the US has given Biomarin's gene therapy against hemophilia special status, which will speed up the approval process. The treatment was rejected in August last year.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
When Biomarin again tries to get the US Food and Drug Administration (FDA) to approve the hemophilia treatment valoctocogene roxaparvovec, it'll get some help along the way.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin awaits crucial approvals and flat growth in 2021
For subscribers
.jpg&w=384&q=75)
